Virtual Library

Start Your Search

Xiujuan Qu



Author of

  • +

    P3.01 - Advanced NSCLC (Not CME Accredited Session) (ID 967)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/26/2018, 12:00 - 13:30, Exhibit Hall
    • +

      P3.01-84 - The Association of CDKN2A Gene Mutation with Clinicopathological Features and Prognosis in Advanced Lung Cancer Patients (ID 12020)

      12:00 - 13:30  |  Presenting Author(s): Xiujuan Qu

      • Abstract

      Background

      The cell cycle-dependent kinase inhibitor gene (CDKN2A) is a tumor suppressor gene, and encodes two kind of cell cycle inhibitor proteins p16INK4a and p14ARF to regulate cell cycle. The aim of this study was to evaluate the association of CDKN2A gene mutation with clinicopathological features and prognosis in Chinese advanced lung cancer patients.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      CDKN2A gene mutation was screened in tumor specimens using second generation sequencing technology. The correlation between CDKN2A gene mutation and clinicopathological characteristics was analyzed by Spearman’s correlation. The overall survival (OS) and progression free survival (PFS) were analyzed by using the Kaplan–Meier method and compared by the log-rank test. The COX model was used to study the single factors and multiple factors. Statistical data was obtained by using SPSS for Windows version 20.0. P values < 0.05 were considered to indicate statistically significant results.

      4c3880bb027f159e801041b1021e88e8 Result

      CDKN2A gene mutation was 4.57 % (10/219) in lung cancer patients. Patients harboring CDKN2A mutation were more commonly observed in squamous carcinoma patients (P = 0.002). Most of patients with CDKN2A gene mutation were progression disease (PD) in the assessment of first-line treatment efficacy, while the patients without CDKN2A mutation were disease control rate (DCR) (P = 0.011). The OS in patients with CDKN2A gene mutation was 19.1 months compared to 42.8 months in patients without mutation (P = 0.010). The PFS in patients with CDKN2A mutation was 3.5 months compared to 9.7 months in patients without mutation (P = 0.000). In addition, multi-factor analysis showed that CDKN2A gene mutation (HR=2.385, P = 0.025), age 60 years or older (HR=1.588, P = 0.027), T4 stage (HR=1.533, P = 0.019) and high ECOG score (HR=1.694, P = 0.009) were independent risk factor for the survival of lung cancer patients.

      8eea62084ca7e541d918e823422bd82e Conclusion

      CDKN2A gene mutation had an important influence on the clinicopathological features and prognosis of Chinese advanced lung cancer patients. The patients with CDKN2A gene mutation had more poor survival.

      6f8b794f3246b0c1e1780bb4d4d5dc53